Skip to main content
. Author manuscript; available in PMC: 2018 Dec 17.
Published in final edited form as: Biochemistry. 2017 Nov 30;57(5):477–478. doi: 10.1021/acs.biochem.7b01126

Figure 1.

Figure 1.

Schematic for midostaurin as a multi-targeted clinical therapeutic for AML. Shown is the structure for midostaurin and a representation of its effects on the human kinome (upper panel). Midostaurin is used in combination with 7+3 induction chemotherapy for patients that have tested positive for mutant FLT3 (lower panel). The kinase dendrogram is adapted and is reproduced with permission from Cell Signaling Inc. Reprinted with permission from Zarrinkar et al. Blood 2009;114:2984–2992.